LAURA HOWLE: Open Payments
NPI 1316537251 · FLORENCE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,486 in 56 payments from 12 companies in 2025. Trend: 2023 $995 · 2024 $1,382 · 2025 $1,486
Food & beverage: $1,486
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $299 |
| E.R. Squibb & Sons, L.L.C. | 9 | $253 |
| Alkermes, Inc. | 8 | $242 |
| ABBVIE INC. | 9 | $167 |
| Janssen Pharmaceuticals, Inc | 5 | $159 |
| Neurocrine BioSciences, Inc. | 7 | $146 |
| Supernus Pharmaceuticals, Inc. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Indivior Inc. | 2 | $34 |
Products named: CAPLYTA, COBENFY, VRAYLAR, INGREZZA, INVEGA SUSTENNA, ARISTADA, LYBALVI, REXULTI.
Industry payments across SC — which companies pay providers there.
